Growth Strategy
Novo Nordisk logo on a window 
Business Strategy
Novo on the ‘ins and outs’ of its nucleic acid growthNovo on the ‘ins and outs’ of its nucleic acid growth
With a mix of feasibility study alliances, R&D collaborations, and outright M&A, Novo Nordisk’s presence in the RNA and gene therapy space now complements its core peptide and protein portfolio.
Subscribe to Our Newsletters
Stay updated and receive your insights for life sciences investment, innovation and partnering directly in your inbox.